A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE)

Trial Profile

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Edoxaban (Primary) ; Enoxaparin sodium; Heparin; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Hokusai-VTE
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 09 Nov 2016 Results published in the Servier Canada Media Release.
    • 09 Nov 2016 According to Servier Canada media release, LIXIANA (edoxaban) has been approved by Health Canada for two indications, prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) based on data from this and ENGAGE AF-TIMI 48 studies.
    • 02 Nov 2016 Results from this and other trial assessing efficacy and safety of edoxaban with rivaroxaban by matched adjusted indirect comparison method presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top